

1 **Fate tracing reveals differences between Reelin⁺ HSCs and Desmin⁺ HSCs**
2 **in activation, migration, and proliferation activities**

3 Ning Chen¹, Shenghui Liu¹, Dan Qin¹, Dian Guan¹, Yaqing Chen¹, Chenjiao
4 Hou¹, Songyun Zheng², Liqiang Wang³, Xiangmei Chen³ and Lisheng Zhang^{1*}

5 1. Bio-medical Center/College of Veterinary Medicine, Huazhong Agricultural
6 University, Wuhan, Hu Bei, 430070, China

7 2. College of Life Science and Technology, Huazhong Agricultural University,
8 Wuhan, 430070, China

9 3. Department of Nephrology, Chinese PLA General Hospital, Chinese PLA
10 Institute of Nephrology, State Key Laboratory of Kidney Diseases, National
11 Clinical Research Center for Kidney Diseases, 28th Fuxing Road, Beijing,
12 100853, China

13 ***Corresponding author:**

14 Lisheng Zhang, PhD, Bio-medical Center/College of Veterinary Medicine,
15 Huazhong Agricultural University, Wuhan, Hubei, 430070, China

16 Tel/fax: +862787282091.

17 E-mail address: lishengzhang@mail.hzau.edu.cn

18

19

20

21

22 **Abstract**

23 The activation of hepatic stellate cells (HSCs) which comprise distinct clusters,
24 is the main cause of liver fibrogenesis in response to different etiologies of
25 chronic liver injuries. In this study, we constructed a novel ReelinCreERT2
26 transgenic mouse in which cells expressing Reelin were fully marked and
27 demonstrated that about 50% HSCs were labeled. These ReelinCreERT2-
28 labeled HSCs displayed distinct characteristics in migration, activation and
29 proliferation compared to Desmin⁺ HSCs (total HSCs) in cholestatic (bile duct
30 ligation; BDL) or hepatotoxic (carbon tetrachloride; CCl₄) liver injuries. In BDL-
31 induced fibrotic livers, Desmin⁺ HSCs were activated with increased
32 proliferation and accumulation activities around the portal triad, but mGFP⁺
33 HSCs did not show proliferation or accumulation activity around the portal triad,
34 and only a small part was activated. In CCl₄-induced fibrotic livers, most of
35 Desmin⁺ and mGFP⁺ HSCs were activated along with proliferation and
36 accumulation potential around the central vein, however fewer mGFP⁺ HSCs
37 were activated compared to Desmin⁺ HSCs. Moreover, in the regression of
38 CCl₄-induced fibrosis, mGFP⁺ HSCs were apoptosed whereas Desmin⁺ HSCs
39 recovered to normal state. Besides, we didn't find evidence that mGFP⁺ HSCs
40 transdifferentiated into hepatocytes or cholangiocytes through mesenchymal-
41 epithelial transition (MET).

42 **Keywords:** Reelin, lineage-tracing, HSCs, activation, accumulation, apoptosis

43

44 **Introduction**

45 Reelin, a secreted extracellular glycoprotein with a molecular weight of 420 kDa,
46 owns two cell surface receptors, the very low-density lipoprotein receptor and
47 the apolipoprotein E receptor (1-3). In vivo and vitro studies show that Reelin is
48 expressed in hepatocytes and up-regulated in patients with liver cirrhosis in the
49 liver and plasma(2, 4). However, some studies reveal that Reelin is expressed
50 both in hepatocytes and hepatic stellate cells (HSCs)(5, 6). Others demonstrate
51 that Reelin is expressed only in HSCs, but not in hepatocytes(7, 8).
52 Besides these, studies show that Reelin is detected in hepatoblasts and oval
53 cells, which differentiate into hepatocytes and cholangiocytes following liver
54 damage(9). Thus, there exists a huge debate over Reelin localization in liver
55 cells and few detailed functions of Reelin in livers have been investigated.

56 HSCs belonging to mesenchymal cells exhibit fibroblast and pericyte
57 characteristics, and compose one third of nonparenchymal cells and 15% of
58 resident cells(10, 11). In normal livers, HSCs laden with retinoid droplets
59 maintain quiescent state and are located in the sinusoidal space of Disse where
60 hepatocytes exchange biomolecules with portal blood(12, 13). Following liver
61 injury, quiescent HSCs are activated and transdifferentiated into migratory,
62 contractile, and proliferative myofibroblasts (MFs) to secrete extracellular
63 matrix (ECM)(14, 15). HSC activation leads to fiber scars accumulation in the
64 space of Disse, which further results in endothelial fenestration loss(12, 16).
65 Numerous specific markers, such as desmin, lecithin-retinol acyltransferase

66 (LRAT), collagen type I (Col1a1), vimentin, glial fibrillary acidic protein (GFAP),
67 smooth muscle actin (α -SMA) and cytoglobin have been used to characterize
68 HSCs genetic targeting, imaging, histological detection, and cell fate tracing(17).
69 Genetic cell lineage tracking labeling of MFs with Col1a1, a major component
70 of the extracellular matrix, has showed that HSCs are the primary source of
71 MFs, occupying approximately 87% of MFs in carbon tetrachloride (CCl₄)-
72 induced liver injury(18). Another study has shown that 82% ~ 96% of MFs are
73 originated from HSCs labeled with LRAT in mice treated with CCl₄, 3,5
74 diethoxycarbonyl-1,4-dihydro-collidin diet or bile duct ligation (BDL)(19). All of
75 these suggest that HSCs are the major source of MFs and the activation of
76 HSCs is the main cause of liver fibrogenesis in response to diverse etiologies.
77 Several studies have reported that mesenchymal-to-epithelial transition (MET)
78 occurs following liver injury and chronic liver inflammation to reduce fibrosis(20-
79 22). Studies using GFAPCre and ACTA2CreERT2-marked mice have
80 demonstrated that HSCs differentiate into hepatocytes and cholangiocytes
81 through MET in injured livers(23-25). Other studies using LratCre- and
82 VimentinCreER-labeled mice have documented no HSCs undergo MET during
83 liver injury(19, 26, 27). So far, whether HSCs undergo MET is still a scientific
84 question to be addressed. After underlying etiology of liver fibrosis is removed,
85 fibrosis scars are gradually regressed(10, 13, 15). In the course of this
86 regression, the activated HSCs undergo apoptosis or revert to a quiescent-like
87 state(28, 29). The apoptosed and inactivated HSCs in the regression of liver

88 fibrosis may be originate from different subsets(30). Promoting HSC apoptosis
89 and repressing HSC activation through pharmacological treatment contributes
90 to liver fibrosis resolution (31). Therefore, facilitating HSC apoptosis and
91 repressing HSC activation have been viewed as a therapeutic target for liver
92 fibrosis(32, 33).

93 Although HSCs play a major role in response to various types of liver fibrosis,
94 the fibrogenic phenotype and mechanisms are different according to the various
95 kinds of etiologies(34, 35). Therefore, a variety of models, such as BDL and
96 CCl₄, are used to mimic hepatopathy of different types to develop better
97 therapeutic strategies (36). BDL and CCl₄ induced liver injuries are two distinct
98 liver fibrosis models that mimics cholestasis (such as primary sclerosing
99 cholangitis and primary biliary cirrhosis) and hepatotoxicity (such as
100 nonalcoholic steatohepatitis and chronic viral hepatitis) respectively(37, 38).

101 Additionally, single-cell RNA sequencing reveals that HSCs are heterogeneous
102 and comprised of distinct populations with different gene-expression in normal
103 and a variety of disease livers and divided into different clusters according to
104 their distinct characteristics of position and function(30, 39, 40). These findings
105 indicate that liver fibrosis treatment should suit the remedy to the case based
106 on fibrogenetic etiologies in different etiologies of liver disease(14).

107 In this study, our genetic cell fate tracking data revealed that ReelinCreERT2-
108 labeled HSCs displayed different characteristics compared to Desmin⁺ HSCs
109 (total HSCs) in BDL-induced and CCl₄-induced fibrotic livers.

110 **Results**

111 **ReelinCreERT2 labels HSCs in sham-operated and BDL-induced fibrotic** 112 **mouse livers.**

113 In order to achieve accurate labelling of Reelin-expressing cells, we constructed
114 Reelin^{CreERT2}; Rosa26mTmG^{flox} (R26T/G^f) mouse model. In this model, after
115 TAM treatment, tomato sequence was excised by Cre, and membrane-tagged
116 green fluorescence protein (mGFP) started to be expressed (**Figure 1A**). When
117 Reelin^{CreERT2}; R26T/G^f mice were injected with TAM, ReelinCreERT2-marked
118 cells in the livers expressed mGFP (**Figure 1B**). Then, we verified whether
119 ReelinCreERT2-mediated mGFP expression matched endogenous Reelin
120 expression in sham-operated and BDL-induced fibrotic mouse livers. Obvious
121 collagen fiber was accumulated after BDL operation (**Supplemental Figure**
122 **1A**), and α -SMA and Col1a1 expression was significantly increased
123 (**Supplemental Figure 1B**) compared to those in sham-operated livers,
124 indicating livers developed significant fibrosis following BDL operation.
125 Immunostaining of mGFP and Reelin in serial section indicated that
126 ReelinCreERT2-mediated mGFP expression almost fully matched endogenous
127 Reelin both in sham-operated and BDL-induced fibrotic mouse livers (**Figure**
128 **1C**). These findings suggest that Reelin^{CreERT2}; R26T/G^f mouse was a credible
129 model to precisely label cells expressing Reelin. Next, we explored what types
130 of cells Reelin located in in mouse livers. Immunohistochemistry of the adult
131 Reelin^{CreERT2}; R26T/G^f mouse livers for mGFP and Desmin showed almost all

132 of mGFP⁺ cells were Desmin⁺ but some Desmin⁺ cells were not mGFP⁺ (**Figure**
133 **1D**), indicating that Reelin was expressed in HSCs and only part of HSCs
134 expressed Reelin rather than hepatocytes, hepatoblasts or oval cells in sham-
135 operated and BDL-induced fibrotic mouse livers.

136 **ReelinCreERT2-labeled HSCs do not migrate or accumulate and only a**
137 **small fraction is activated in BDL-induced fibrotic livers.**

138 As Reelin was expressed only in part of HSCs by immunostaining of mGFP and
139 Desmin, we investigated whether there were differences between Desmin⁺
140 HSCs and mGFP⁺ HSCs. Immunohistochemistry of mGFP and Desmin with
141 Glutamine Synthetase (GS, a marker of central vein) showed that both mGFP⁺
142 and Desmin⁺ HSCs were scattered throughout the parenchyma in sham-
143 operated livers (**Figure 2A**). Whereas in BDL-induced fibrotic livers, Desmin⁺
144 HSCs were accumulated around the portal triad, and mGFP⁺ HSCs were
145 scattered throughout the parenchyma (**Figure 2B**). These findings suggest
146 significant differences exist in migration capacity and location between Desmin⁺
147 and mGFP⁺ HSCs in BDL-induced liver fibrosis. Next, we explored activation
148 ability of mGFP⁺ HSCs. Immunostaining of mGFP with α -SMA showed that
149 mGFP⁺ HSCs did not express α -SMA in sham-operated livers, however, α -
150 SMA was expressed in mGFP⁺ HSCs in BDL-induced fibrotic livers (**Figure 2C**),
151 which indicated that mGFP⁺ HSCs were activated in fibrotic livers induced by
152 BDL. Immunostaining of α -SMA with Desmin and mGFP in serial sections
153 showed that a large proportion of Desmin⁺ HSCs (72.35% Desmin⁺ HSCs)

154 expressed α -SMA, but only 31.01% mGFP⁺ HSCs expressed α -SMA in BDL-
155 induced fibrotic livers (**Figure 2D**). To confirm the finding that fewer mGFP⁺
156 HSCs were activated than Desmin⁺ HSCs, we analyzed serial sections
157 immunostaining of Col1a1 with mGFP or Desmin, and got similar results as
158 shown in **Figure 2E** that Col1a1 was expressed in 48.53% mGFP⁺ HSCs while
159 expressed in 89.34% Desmin⁺ HSCs.

160 **ReelinCreERT2-labeled HSCs do not show distinguished proliferation**
161 **activity in BDL-induced fibrotic livers.**

162 The migration, proliferation and activation of HSCs are an accompanying
163 process(10, 12). There were significant differences in migration and activation
164 activities between mGFP⁺ and Desmin⁺ HSCs, so we want to know the
165 proliferative capacity difference between mGFP⁺ and Desmin⁺ HSCs.
166 Immunohistochemical staining of Desmin and mGFP showed the number of
167 Desmin⁺ HSCs increased remarkably in BDL-induced fibrotic livers compared
168 to sham-operated livers (**Figure 3A**), but the number of mGFP⁺ HSCs were
169 comparable (**Figure 3B**). Co-staining of mGFP and Desmin showed the
170 percentage of mGFP⁺ HSCs accounted for Desmin⁺ HSCs was 49.83% in
171 sham-operated livers but decreased to 23.84% in BDL-induced fibrotic livers
172 (**Figure 3C**), which further confirmed that the number of Desmin⁺ HSCs
173 increased remarkably but the number of mGFP⁺ HSCs had no significant
174 difference in BDL-induced fibrotic livers. Bromodeoxyuridine (BrdU) labeling
175 showed the percentage of Desmin⁺ HSCs with BrdU was 4.74% in sham-

176 operated livers and increased to 9.58% in BDL-induced livers, but the
177 percentage of mGFP⁺ HSCs labeled by BrdU did not change much (4.34% in
178 sham-operated livers and 3.31% in BDL-induced livers) (**Figure 3D**).
179 Immunostaining of Ki67 and mGFP or Desmin got a similar result that the
180 proliferation ratio of Desmin⁺ HSCs increased greatly (6.57% in sham-operated
181 livers and increased to 10.59% in BDL-induced fibrotic livers), but the ratio of
182 mGFP⁺ HSCs had no notable difference (5.84% in sham-operated livers and
183 5.33% in BDL-induced fibrotic livers) (**Figure 3E**). Considering the factors, such
184 as changes of cell number, proliferation rate, and the percentage of mGFP⁺
185 HSCs accounted for Desmin⁺ HSCs in normal and BDL-induced fibrotic livers,
186 we conclude that the number of Desmin⁺ HSCs increased greatly, but the
187 proliferative ratio of mGFP⁺ HSCs in BDL-induced fibrotic livers was not
188 remarkably different from sham-operated livers.

189 **mGFP⁺ HSCs accumulate around central vein in CCl₄-induced liver injury.**

190 BDL initially induced biliary duct hyperplasia and further caused biliary fibrosis,
191 however, CCl₄-induced liver fibrosis started on pericentral cell injury and formed
192 fibrous septum (**Supplemental Figure 1C**). For this reason, we explored
193 whether there were differences in migration, activation and proliferation
194 potentials between mGFP⁺ HSCs and Desmin⁺ HSCs in CCl₄-induced liver
195 injury. After treated with CCl₄ for 6 weeks, obvious collagen fiber was observed
196 by Sirius red staining (**Supplemental Figure 2A**) and immunostaining showed
197 that the expression of α -SMA and Col1a1 was significantly increased.

198 **(Supplemental Figure 2B)**, which indicated that Reelin^{CreERT2}; R26T/G^f mice
199 developed severe fibrosis. Serial section immunohistochemistry of Reelin and
200 mGFP in normal and CCl₄-induced fibrotic livers of TAM-treated Reelin^{CreERT2};
201 R26T/G^f mice showed mGFP expression almost fully matched endogenous
202 Reelin, which was similar to immunohistochemistry staining of Reelin and
203 mGFP in sham-operated and BDL-induced fibrotic livers **(Figure 4A)**.
204 Immunohistochemistry for mGFP with Desmin and α -SMA also showed mGFP
205 was expressed in HSCs in normal and CCl₄-induced fibrotic livers **(Figure 4B)**
206 and mGFP⁺ HSCs were activated in CCl₄-induced fibrotic livers **(Figure 4C)**.
207 Besides, we observed that mGFP⁺ and Desmin⁺ HSCs were scattered
208 throughout the parenchyma in normal livers **(Figure 4D)**, but both of them were
209 accumulated around the central vein in CCl₄-induced fibrotic livers **(Figure 4E)**.
210 These findings indicate that the migration activity of Reelin⁺ HSCs in CCl₄-
211 induced fibrotic livers was significantly different with that in BDL-induced fibrotic
212 livers.

213 **mGFP⁺ HSCs share similarity with Desmin⁺ HSCs in proliferation but**
214 **fewer cells are activated compared to Desmin⁺ HSCs in CCl₄-induced**
215 **fibrotic livers.**

216 Next, we explored mGFP⁺ HSC's activation and proliferation properties in CCl₄-
217 induced fibrotic livers. In CCl₄-induced fibrotic livers of Reelin^{CreERT2};
218 R26T/G^f mice, the Immunohistochemistry results showed that 60.43% mGFP⁺
219 HSCs expressed α -SMA and the proportion of Desmin⁺ HSCs expressed α -

220 SMA was 80.37% (**Figure 5A**). Meanwhile, 75.38% mGFP⁺ HSCs and 85.42%
221 Desmin⁺ HSCs expressed Col1a1 (**Figure 5B**). The above results indicated that
222 fewer mGFP⁺ HSCs were activated than Desmin⁺ HSCs in CCl₄-induced fibrotic
223 livers. And immunostaining of Desmin and mGFP showed that the number of
224 Desmin⁺ HSCs and mGFP⁺ HSCs was increased greatly in CCl₄-treated fibrotic
225 livers (**Figure 5C and D**). However, co-staining of mGFP and Desmin revealed
226 that the percentage of mGFP⁺ HSCs accounted for Desmin⁺ HSCs had no
227 significant difference in CCl₄-treated fibrotic livers compared to that in normal
228 livers (**Figure 5E**), which indicated there was no significant difference between
229 Desmin⁺ and mGFP⁺ HSCs in regarding to proliferative property. So, we further
230 investigated the proliferative property of mGFP⁺ HSCs and Desmin⁺ HSCs by
231 BrdU labeling and Ki67 staining in normal and CCl₄-treated livers. Our results
232 documented that Desmin⁺ and mGFP⁺ HSCs had superior proliferation ability
233 in CCl₄-treated livers compared to normal livers, but the proliferation rate was
234 comparable between Desmin⁺ and mGFP⁺ HSCs (**Figure 5F and G**). Based on
235 the immunohistochemistry staining for mGFP and Desmin with α -SMA, Col1a1,
236 BrdU and Ki67, we conclude that, in CCl₄-induced injured livers, mGFP⁺ HSCs
237 shared similarities with Desmin⁺ HSCs in proliferation property but still fewer
238 mGFP⁺ HSCs were activated compared to Desmin⁺ HSCs.

239 **ReelinCreERT2-labeled HSCs do not transdifferentiate into hepatocytes**
240 **or cholangiocytes in healthy or injured livers.**

241 HSCs transdifferentiating into hepatocytes or cholangiocytes in injured livers is
242 controversial(21, 27, 41). To verify whether HSCs are able to transdifferentiate
243 into hepatocytes and cholangiocytes, we tested ReelinCreERT2-labeled HSCs
244 transformation in sham-operated and BDL-induced fibrotic livers. However,
245 analyzed immunohistochemistry for mGFP with hepatocyte nuclear factor 4
246 alpha (HNF4 α) showed no mGFP⁺ HSCs were observed with typical
247 hepatocyte nuclear morphology or expressed HNF4 α both in sham-operated
248 and BDL-induced fibrotic livers (**Figure 6A**). Moreover, immunostaining of
249 mGFP with cytokeratin 19 (CK19) observed no mGFP⁺ HSCs expressed CK19
250 either (**Figure6B**). Although we did not observe ReelinCreERT2-labeled HSCs
251 transdifferentiated into hepatocytes or cholangiocytes in BDL-induced fibrotic
252 livers, in consideration of the different mechanism between BDL-induced and
253 CCl₄-induced liver fibrosis, we tested whether ReelinCreERT2-labeled HSCs
254 transdifferentiate into hepatocytes or cholangiocytes through MET in CCl₄-
255 induced fibrotic livers. Immunostaining of mGFP with HNF4 α or CK19 in normal,
256 CCl₄-treated, CCl₄-treated following 7 days recovery or CCl₄-treated following 3
257 weeks recovery livers showed no mGFP⁺ HSCs expressed HNF4 α or CK19
258 (**Figure 6C and 6D**). Collectively, these findings exclude the possibility that
259 ReelinCreERT2-marked HSCs transdifferentiated into hepatocytes or
260 cholangiocytes through MET in healthy or injured livers.

261 **ReelinCreERT2-labeled HSCs undergo apoptosis in CCl₄-induced liver**
262 **fibrosis regression.**

263 We further investigated mGFP⁺ HSC's cell fate in livers recovered from CCl₄-
264 induced injury. Sirius red staining showed collagen fiber deposited obviously in
265 CCl₄-treated livers and regressed markedly in livers recovered from CCl₄-
266 induced injury (**Supplemental Figure 2C**). Immunostaining of Desmin and
267 mGFP showed, in CCl₄-induced fibrotic livers, Desmin⁺ and mGFP⁺ HSCs
268 proliferated notably and after 5 week's recovery from CCl₄-induced injury the
269 number of Desmin⁺ HSCs returned to normal, whereas few mGFP⁺ HSCs were
270 left (**Figure 7A and B**). The percentage of mGFP⁺ HSCs accounted for
271 Desmin⁺ HSCs was 48.08% in normal livers and 50.49% in CCl₄-induced
272 fibrotic livers, but decreased to 5.60% in livers recovered from CCl₄-induced
273 injury for 5 weeks (**Figure 7C**). Early study reported that HSCs underwent
274 apoptosis in livers 7 days after CCl₄ cessation. We speculated the disappeared
275 mGFP⁺ HSCs were due to apoptosis, and our immunohistochemical results
276 approved that mGFP⁺ HSCs underwent apoptosis in livers recovered from
277 CCl₄-induced injury for 7 days (**Figure 7D**). Moreover, serial section
278 immunohistochemistry showed 3.83% Desmin⁺ HSCs underwent apoptosis
279 and 7.26% mGFP⁺ HSCs underwent apoptosis which was almost 2 times as
280 high as the percentage of Desmin⁺ HSCs undergoing apoptosis (**Figure 7E**).
281 These findings indicated that mGFP⁺ HSCs were more susceptible to apoptosis
282 than Desmin⁺ HSCs.

283 To ensure our findings that mGFP⁺ HSCs were a different subset compared to
284 total HSCs, we chose Vimentin as another total HSC marker(17).

285 Immunohistochemistry of Desmin and Vimentin in sham-operated and BDL-
286 induced livers showed that Vimentin⁺ HSC's characteristics were similar to
287 Desmin⁺ HSC's (**Supplemental Figure 3A**), and immunostaining of mGFP and
288 Desmin or Vimentin showed that the percentage of mGFP accounted for
289 Vimentin⁺ HSCs had no difference compared to Desmin⁺ HSCs
290 (**Supplemental Figure 3B**). And the results of immunohistochemistry of mGFP
291 and Desmin or Vimentin in normal and CCl₄-treated livers were consistent with
292 results in sham-operated and BDL-induced livers (**Supplemental Figure 3C**
293 **and D**).

294 **Discussion**

295 Reelin as a serine protease, play an important role in brain (42, 43). But which
296 type of cells in livers expressing Reelin was controversial. Cell lineage tracing
297 is a technique to track cell fate based on cre-lox system, revealing self-renewal,
298 differentiation and migration of specific types of cells in development, disease
299 and regeneration(23). Early studies applied cell lineage tracing to confirm a
300 certain cell lineage is stem cells or investigate epithelial-to-mesenchymal
301 transition (EMT) and MET(21). In our study, we pioneeringly changed the
302 conventional usage of cell lineage tracing and applied this technique to
303 demonstrate that Reelin was expressed in HSCs using Reelin^{CreERT2}; R26T/G^f
304 mouse model and these ReelinCreERT2-labeled HSCs were a new subset,
305 which displayed different characteristics compared to Desmin⁺ HSCs in vivo.
306 We investigated properties of mGFP⁺ (Reelin⁺) HSCs and Desmin⁺ HSCs in

307 activation, migration, and proliferation in BDL-induced and CCl₄-induced fibrotic
308 livers. Our results showed that in BDL-induced fibrotic livers, Desmin⁺ HSCs
309 accumulated around the portal vein with significant proliferation and activation,
310 whereas Reelin⁺ HSCs did not migrate either proliferate, and only a small part
311 was activated compared to Desmin⁺ HSCs. HSC's activation and proliferation
312 usually are considered as a accompanying process(10), but our results indicate
313 that the processes of activation and proliferation of HSCs are independent in
314 some degree under certain conditions. And we observed that CCl₄-Reelin⁺
315 HSCs exhibited similarity to CCl₄-Desmin⁺ HSCs rather than BDL-Reelin⁺ HSCs.
316 In CCl₄-induced fibrotic livers, both of Desmin⁺ HSCs and Reelin⁺ HSCs
317 accumulated around the central vein with remarkable proliferation activity, but
318 the proliferative rate between Desmin⁺ and Reelin⁺ HSCs had no significant
319 differences. The activation potential analysis of Desmin⁺ HSCs and Reelin⁺
320 HSCs showed Desmin⁺ HSCs and Reelin⁺ HSCs were both activated markedly,
321 but fewer mGFP⁺ HSCs were activated compared to Desmin⁺ HSCs. Single-
322 cell RNA sequencing is also a powerful method to identify a certain type of cell's
323 characteristics and has demonstrated distinct HSC clusters exist in normal or
324 injured livers(9, 30). But physiological conditions are different from in vitro
325 culture environments, for instance, cellular microenvironment, cytokines, cell-
326 cell junction, et al, which might change the gene expression and chromatin state
327 of HSCs(44, 45). So, single-cell RNA sequencing might get an incorrect result
328 because of the difference of physiological conditions and in vitro culture

329 environments. Compared to Single-cell RNA sequencing, our cell lineage
330 tracing findings are closer to Reelin⁺ HSCs physiological properties in vivo.

331 To verify HSCs transforming into hepatocytes and cholangiocytes through MET,
332 we traced Reelin⁺ HSC's fate both in BDL-induced and CCl₄-induced injured
333 livers and we observed no Reelin⁺ HSCs expressed CK19 or HNF4 α . In
334 consideration of ReelinCreERT2 only marked about 50% HSCs, it is still
335 possible that HSCs not marked by ReelinCreERT2 differentiate into
336 cholangiocytes or hepatocytes through MET. Whether HSCs differentiating
337 into cholangiocytes or hepatocytes through MET should be further investigated.

338 Unexpectedly, in the regression of fibrosis, Desmin⁺ HSC's number decreased
339 to normal, but Reelin⁺ HSCs accounting for about 50% Desmin⁺ HSCs almost
340 all disappeared because of apoptosis. Combining the early researches which
341 reported that 50% of HSCs underwent inactivation during the liver injury
342 recovery(28, 29), we speculated that Reelin⁺ HSCs underwent apoptosis and
343 Reelin⁻ HSCs underwent inactivation in the regression of fibrosis.

344 We have not elucidated why there are marked differences in migration,
345 activation and proliferation among BDL-Reelin⁺ HSCs, CCl₄-Reelin⁺ HSCs,
346 BDL-Desmin⁺ HSCs, and CCl₄-Desmin⁺ HSCs. HSCs are main source of MFs
347 independent of etiologies. In consideration of the heterogeneity of HSCs,
348 properties of distinct clusters of HSCs are various in the same or different
349 etiologies(30, 40). Portal fibroblasts (PFs) also are activated in BDL-induced
350 liver injury, which are accumulated around the portal area and play a crucial

351 part at the early stage of BDL-induced liver fibrosis(46, 47), and promote HSCs
352 activation(18). Based on the findings that both of PFs and HSCs accumulating
353 around the portal area(8, 47), and Reelin⁺ HSCs scattered throughout the
354 parenchyma, we speculate PFs may have more effects on Desmin⁺ HSCs
355 rather than Reelin⁺ HSCs though we did not investigate the interaction between
356 PFs, Desmin⁺ HSCs, and Reelin⁺ HSCs. Additionally, the mechanisms of
357 fibrogenesis are different in BDL and CCl₄ induced liver injuries(35). BDL mainly
358 results in obstruction of bile flow and increased biliary pressure which further
359 gives rise to hyperplasia of biliary epithelial cells, causing cholestatic injury that
360 progress to periportal fibrosis and cirrhosis(36). While CCl₄ is hepatotoxic,
361 leading to free radical reactions, lipid peroxidation, inflammatory response and
362 necrosis of hepatocytes, and gives rise to an initial pericentral matrix
363 deposition(38, 48). The differences in migration, activation and proliferation
364 activities between Reelin⁺ HSCs and Desmin⁺ HSCs in BDL and CCl₄ induced
365 liver fibrosis maybe also caused by the model-specific influence.

366 In conclusion, we pioneeringly using cell lineage tracing have demonstrated that
367 ReelinCreERT2-labeled HSCs are a new cluster which displays different
368 characteristics compared to Desmin⁺ HSCs in BDL-induced and CCl₄-induced
369 fibrotic livers. And our findings enlighten that treating liver fibrosis caused by
370 different etiologies should suit the remedy to the case, for instance, focusing on
371 Reelin⁺ HSCs may be a good therapy target in CCl₄-induced liver fibrosis

372 (hepatotoxic injury), however, controlling the Reelin⁻ HSCs may optimize the
373 therapeutic effects in BDL-induced liver fibrosis (cholestatic injury).

374 **Materials and methods**

375 **Mice**

376 The animals in this study were against a C57BL6/J background. Rosa26mTmG
377 reporter mice were obtained from Jackson Laboratory. ReelinCreERT2 mice
378 were constructed by Biocytogen (Beijing, China). The P2A-iCreERT2 cassette
379 was inserted after the stop codon TGA of Exon64 of Reelin and the knock-in
380 mice were prepared based on the CRISPR/Cas9-based system developed by
381 Biocytogen. ReelinCreERT2 mice were crossed with Rosa26mTmG reporter
382 mice to generate Reelin^{CreERT2}; Rosa26mTmG^{flox} (R26T/G^f) mice used for
383 subsequent experiments. ReelinCreERT2 genotype identification was
384 performed by using forward primer 5'-CTCTGCTGCCTCCTGGCTTCT and
385 reverse primer 5'-TCAATGGGCGGGGGTTCGTT. Rosa26mTmG reporter mice
386 genotype identification was conducted by using forward primer 5'-
387 TATTCTGTCCCTAGGCGGTGAAGTCT and reverse primer 5'-
388 CCTGTCCCTGAACATGTCCATCAG. All animal experiment procedures were
389 in accordance with guidelines of Huazhong Agricultural University Guidelines
390 for the Care and Use of Laboratory Animals.

391 **Fibrosis Induction and Tamoxifen Injection**

392 Hepatic fibrosis was induced by intraperitoneal injections of carbontetrachloride
393 (CCl₄) (Aladdin, C112043, Shanghai, China) at the dose of 1ml/kg body weight,
394 two times a week for 6-week (n=7), followed by 7-day (n=4), 3-week (n=6), or
395 5-week (n=6) recovery or induced by BDL for 2 weeks (n=5). CCl₄ was
396 dissolved in corn oil (Aladdin, C116023) at a ratio of 1:4. The number of mice
397 treated with vehicle was 6 and the number of sham-operated mice was 3.
398 ReelinCreERT2 activity was induced by intraperitoneal injections of tamoxifen
399 (Sigma, T5648, Missouri, USA) at the dose of 100 mg/kg on daily basis for 3
400 days starting 7 days before the first CCl₄ injection. Bromodeoxyuridine (BrdU)
401 (Sigma, B5002) was injected at the dose of 50 mg/kg body weight every two
402 hours for 4 times, the last injection was taken 24 hours before sacrifice.

403 **Tunel (terminal deoxynucleotidyl transferase dUTP nick end labeling)**

404 We detected DNA fragmentation resulting from apoptotic signaling cascades
405 with the In Situ Cell Death Detection Kit Fluorescein (Roche, 11684795910,
406 Basel, Switzerland) according to manufacturer's instructions. The presence of
407 nicks in the DNA was identified by terminal deoxynucleotidyl transferase (TdT),
408 an enzyme that catalyzed the addition of labeled dUTPs. The samples were
409 digested with DNase and used as staining positive control.

410 **Immunofluorescent Assay**

411 Samples were fixed in 4% paraformaldehyde (PFA), embedded in paraffin, cut
412 into 4 μm sections, dewaxed, hydrated, and subsequently incubated with

413 antibodies. Fluorescence was bleached with 3% H₂O₂ in methanol for 15
414 minutes. For antigen retrieval, samples were heated in 10 mM sodium citrate
415 buffer (pH 6.0) for 20 minutes. Sections were blocked with 10% goat serum for
416 30 minutes and incubated with primary antibodies, anti-GFP (Proteintech,
417 50430-AP, Wuhan, China), anti-GFP (Santa Cruz, sc-9996, Texas, USA), anti-
418 desmin (Servicebio, GB12081, Wuhan, China), anti-GS(glutamine synthetase)
419 (Santa Cruz, sc-74430), anti-CK19 (Servicebio, GB12197), and anti-
420 HNF4 α (Abcam, Ab41898, Cambridgeshire, UK), anti-Vimentin (Abcam,
421 Ab92547), anti-Casp3 (Proteintech, 19677-1-AP), anti-BrdU (Servicebio,
422 GB12051), anti-Ki67(Invitrogen, PA5-19462, Massachusetts, USA).
423 Subsequently, sections were incubated with fluorophore-conjugated secondary
424 antibodies (2.5 μ g/ml, Invitrogen, A-11034, A-21424), nuclei co-staining with 4,
425 6-diamidino-2-phenylindole (DAPI) (Abcam, ab104139). Images were acquired
426 with a laser scanning confocal microscope (Carl Zeiss Microscopy, LSM710,
427 Jena, Germany), and were analyzed by Zen software with fixed parameters.

428 **Histology and immunohistochemistry**

429 Liver tissues were immobilized with 4% PFA, dehydrated, embedded in paraffin,
430 sectioned at 4 μ m, and processed for Sirius red staining and
431 immunohistochemistry. Immunohistochemistry was performed with antibodies,
432 anti-GFP (Santa Cruz, sc-9996) and anti-Reelin (NOVUS, NB600-1081,
433 Minneapolis, USA). Subsequently sections were incubated with
434 diaminobenzidine (Gene Tech Company Limited, GK347011, Shanghai, China)

435 and counterstaining with hematoxylin (Servicebio, GB1004). All steps of
436 immunohistochemistry are according to manufacturer's instructions.

437 **Software–Intensity measurement**

438 Image Pro Plus (Image Pro Plus v.7: Media Cybernetics; Bethesda, MD), as an
439 analysis program, was used to analyze and quantify data from
440 photomicrographs. In this study, the analyses were performed as follows:
441 Integrated Optical Density (IOD) Image Pro Plus was used to quantify the
442 intensity of probes binding to the structures. We used the confocal series to
443 calculate the total binding intensity of the probes (IOD-intensity value).

444 **Statistical analysis**

445 Statistical analyses were performed using the GraphPad Prism 6(GraphPad).
446 Data are expressed as means \pm SEM. Comparisons between two groups were
447 performed using the two-tailed Student's t-test. Comparisons between multiple
448 groups were performed using ordinary one-way ANOVA with the Dunnett's
449 multiple comparison test. Statistical significance was presented at the level of
450 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

451 **Acknowledgements**

452 This work was supported by National Key R&D Plan no. 2017YFA0103202 and
453 no. 2017YFA0103200, National Natural Science Foundation of China
454 32071143, the Fundamental Research Funds for the Central Universities
455 (2662019YJ008), and Huazhong Agricultural University Startup funds. We are
456 thankful to Nannan Niu, and Bingjie Li (Huazhong Agricultural University) for

457 critical reading of the manuscript.

458 **Author contributions**

459 N. C. and L. Z. conceived and designed the study; N. C. provided the
460 experimental data; N.C. and S.L. performed the experiments; D.Q., D.G., Y.C.,
461 C.H., and S.Z. provided assistance in animal experiments; N.C. and L. Z.
462 discussed and drafted the manuscript; L. W. and X. C reviewed the manuscript;
463 L.Z and N.C. organized the data and wrote the manuscript.

464 **Competing interests**

465 The authors declare that there is no conflict of interests regarding the
466 publication of this paper.

467 **Ethic statement**

468 All animal experiments conducted were compliant with Huazhong Agricultural
469 University Guidelines for the Care and Use of Laboratory Animals

470 **Data availability**

471 The data that support the findings of this study are available from the
472 corresponding author upon reasonable request.

473


474

475

476

477


478 **Figures**



479

480 **Figure 1. Reelin is expressed in HSCs in the sham and BDL treated livers.**


481 **A.** Schematic diagram showing mTom/mGFP reporter gene expression in the absence and presence of
482 tamoxifen-inducible CreERT2-mediated recombination. **B.** After treated with TAM, mGFP was induced in
483 Reelin^{CreERT2}; R26T/G^f mice. **C.** Livers from sham or BDL-operated Reelin^{CreERT2}; R26T/G^f mice were
484 stained with anti-Reelin and anti-GFP antibodies, and analyzed immunohistochemistry demonstrating
485 overlap between ReelinCreERT2-induced mGFP expression and endogenous Reelin expression in serial
486 sections. **D.** Immunohistochemistry of the sham or BDL-operated adult Reelin^{CreERT2}; R26T/G^f mouse
487 livers for mGFP with Desmin demonstrated that Reelin was expressed in HSCs and only part of HSCs
488 expressed mGFP. Scale bar in B and D represents 20 μm. Scale bar in C represents 50 μm.



489


490 **Figure 2. ReelinCreERT2 labeled HSCs do not accumulate and fewer cells are activated compared**
 491 **to Desmin⁺ HSCs in BDL-induced fibrotic livers.**

492 **A.** mGFP and Desmin costaining with GS in sham-operated Reelin^{CreERT2}; R26T/G^f mouse liver
 493 determined that mGFP⁺ HSCs and Desmin⁺ HSCs were scattered throughout the parenchyma. **B.** mGFP
 494 and Desmin costaining with GS in BDL-operated Reelin^{CreERT2}; R26T/G^f mouse liver for 2 weeks indicated
 495 that Desmin⁺ HSCs accumulated around the portal vein (pv), whereas mGFP⁺ HSCs were scattered
 496 throughout the parenchyma. **C.** mGFP⁺ HSCs were activated in BDL-induced Reelin^{CreERT2}; R26T/G^f
 497 mouse fibrotic livers observed by immunohistochemistry of mGFP and α -SMA. **D.** Immunohistochemistry
 498 of the BDL-induced fibrotic livers for Desmin with α -SMA and mGFP with α -SMA observed that fewer
 499 mGFP⁺ HSCs expressed α -SMA. **E.** Analyzed immunohistochemistry of the BDL-induced fibrotic livers for
 500 Desmin with Col1a1 and mGFP with Col1a1 determined that fewer mGFP⁺ HSCs expressed Col1a1. Data
 501 are reported as means \pm SEM. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar in A and B represents 50 μ m.
 502 Scale bar in C, D, and E represents 20 μ m.




503 **Figure 3. ReelinCreERT2 labeled HSCs do not show proliferation capacity in BDL-induced fibrotic**
 504 **livers.**

505 **A.** The number of Desmin⁺ HSCs increased significantly in BDL-induced liver injury observed by
 506 immunohistochemistry of Desmin⁺ HSCs. **B.** Analyzed immunohistochemistry of mGFP⁺ HSCs indicated
 507 that the number of mGFP⁺ HSCs was not increased in injured livers induced by BDL. **C.** The percentage
 508 of mGFP⁺ HSCs accounted for Desmin⁺ HSCs was significantly reduced in Reelin^{CreERT2}; R26T/G^f mouse
 509 fibrotic livers determined by BDL Immunostaining of mGFP and Desmin. **D.** Proliferative properties of
 510 Reelin⁺ HSCs and Desmin⁺ HSCs determined by immunohistochemistry for BrdU with Desmin or mGFP
 511 demonstrated that Desmin⁺ HSCs proliferative properties significantly increased in BDL-induced liver
 512 fibrosis comparing to sham-operated livers, but mGFP⁺ HSCs proliferative properties had no difference.
 513 **E.** Immunohistochemistry for Ki67 with Desmin or mGFP demonstrated that Desmin⁺ HSCs proliferative
 514 properties significantly increased in BDL-induced liver fibrosis comparing to sham-operated livers, but
 515 mGFP⁺ HSCs proliferative properties had no difference. Data are reported as means \pm SEM. * $p < 0.05$;
 516 ** $p < 0.01$; *** $p < 0.001$. Scale bar represents 20 μm .




517 **Figure 4. Genetically labeled Reelin⁺ HSCs accumulate around the central veins and fibrous septa**
518 **in CCl₄-induced injured livers.**

519 **A.** Immunostaining of Reelin and mGFP in vehicle-treated or CCl₄-treated Reelin^{CreERT2}; R26T/G^f mouse
520 livers for 6-week demonstrated overlap between endogenous Reelin expression and Reelin^{CreERT2}-
521 induced mGFP expression in serial sections. **B.** Immunohistochemistry of normal or fibrotic livers induced
522 by CCl₄ for mGFP and Desmin showed that mGFP was located in part of HSCs. **C.** Activated mGFP⁺
523 HSCs were observed in CCl₄-induced fibrotic livers by immunostaining of mGFP and α-SMA. **D.**
524 Immunohistochemistry of normal livers for GS with mGFP or Desmin showed mGFP⁺ HSCs and Desmin⁺
525 HSCs were scattered throughout the parenchyma. **E.** Immunohistochemistry of CCl₄-induced fibrotic livers
526 for GS with mGFP or Desmin showed both mGFP⁺ HSCs and Desmin⁺ HSCs accumulated around the
527 central veins (cv) and fibrous septa. Scale bar in A represents 100 μm. Scale bar in B and C represents
528 100 μm. Scale bar in A represents 50 μm.



529 **Figure 5. Fewer GFP⁺ HSCs are activated compared to Desmin⁺ HSCs in CCl₄-induced injured**
 530 **livers.**


531 **A.** Analyzed immunohistochemistry of Reelin^{CreERT2}; R26T/G^f mice treated with CCl₄ for 6-week for α -SMA
 532 with mGFP or Desmin demonstrated that fewer mGFP⁺ HSCs expressed α -SMA. **B.** Immunostaining for
 533 Col1a1 with mGFP or Desmin observed that fewer mGFP⁺ HSCs expressed Col1a1. **C.** Immunostaining
 534 of mGFP and Desmin displayed that the number of Desmin⁺ HSCs and mGFP⁺ HSCs was significantly
 535 increased in CCl₄-induced fibrotic livers. **D.** Quantification data of Desmin⁺ HSCs and mGFP⁺ HSCs. **E.**
 536 Analyzed immunostaining of mGFP and Desmin indicated that the percentage of mGFP⁺ HSCs accounted
 537 for Desmin⁺ HSCs had no significant difference in fibrotic livers induced by CCl₄ compared to in normal
 538 livers. **F.** Proliferative properties of Reelin⁺ HSCs were determined by BrdU costaining with desmin or
 539 mGFP in serial sections of the mice treated with vehicle or CCl₄ for 6-week, and Desmin⁺ HSCs and
 540 mGFP⁺ HSCs showed significant proliferation activity following CCl₄ injection. **G.** Proliferative properties
 541 of Desmin⁺ HSCs and GFP⁺ HSCs were determined by Ki67 in Desmin⁺ HSCs and GFP⁺ HSCs. Data are
 542 reported as means \pm SEM. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar represents 20 μ m.



543

544 **Figure 6. Genetically labeled Reelin⁺ HSCs do not undergo MET in response to chronic liver injury**
545 **or recovery from fibrosis.**


546 **A.** No genetically labeled mGFP⁺ HSCs was observed expressing hepatocytes marker HNF4 α in sham-
547 sham-operated livers or BDL-induced fibrotic livers. **B.** Genetically labeled mGFP⁺ HSCs did not express
548 cholangiocytes marker CK19 in sham-operated livers or BDL-induced fibrotic livers. **C.** Genetically labeled
549 mGFP⁺ HSCs in livers treated with vehicle or in livers in response to CCl₄ for 6-week, recovery from CCl₄
550 for 7-day or 3-week did not express hepatocytes marker HNF4 α in ReelinCreERT2 mice. **D.** Genetically
551 labeled mGFP⁺ HSCs in normal livers or in livers in response to CCl₄ for 6-week, recovery 7-day or 3-
552 week from CCl₄ in ReelinCreERT2 mice did not express cholangiocytes marker CK19. Scale bar
553 represents 20 μ m.



554

555 **Figure 7. Reelin⁺ HSCs undergo apoptosis during recovery from CCl₄-induced liver fibrosis.**

556 **A.** Immunostaining of Desmin in Reelin^{CreERT2}; R26T/G^f mouse livers indicated that the number of Desmin⁺
557 HSCs recovered to normal level after CCl₄ treatment was terminated for 5 weeks. **B.** Few mGFP⁺ HSCs
558 existed after 5 weeks recovery from chronic CCl₄ injury by analyzing immunohistochemistry of liver for
559 mGFP. **C.** Immunohistochemistry for mGFP with Desmin observed that the percentage of mGFP⁺ HSCs
560 accounted for Desmin⁺ HSCs was reduced significantly during recovery from CCl₄-induced liver fibrosis.
561 **D.** Apoptosed mGFP⁺ HSCs were observed by TUNEL in Reelin^{CreERT2}; R26T/G^f mouse livers recovery 7
562 days from CCl₄-induced liver fibrosis. **E.** Immunohistochemistry for TUNEL with mGFP or Desmin
563 demonstrated that mGFP⁺ HSCs were more likely to undergo apoptosis than Desmin⁺ HSCs in serial
564 sections. Data are reported as means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar represents
565 20 μm.



566

567 **Figure 8. Graphical Abstract.**

568 ● Cell lineage tracing reveals that about 50% HSCs are marked by ReelinCreERT2, and properties of
 569 these ReelinCreERT2-marked HSCs (Desmin⁺ Reelin⁺ HSCs) are different from Desmin⁺ Reelin⁻
 570 HSCs.


571 ● In cholestatic injury model, Desmin⁺ Reelin⁻ HSCs are accumulated around the portal triad with a
 572 significant activation and proliferation activity, but Desmin⁺ Reelin⁺ HSCs do not show proliferation
 573 or migration to the portal triad, and only a small part is activated.

574 ● In hepatotoxic injury model, Desmin⁺ Reelin⁺ HSCs share similarities with Desmin⁺ Reelin⁻ HSCs in
 575 migration, proliferation and activation, nonetheless, still fewer Desmin⁺ Reelin⁺ HSCs are activated.

576 ● In the regression of liver fibrosis, Desmin⁺ Reelin⁺ HSCs are apoptosed.

577


578 **Supplemental Figures**



579

580 **Supplemental Figure 1. BDL induces severe biliary fibrosis.**


581 **A.** Sirius red staining displayed that severe biliary fibrosis was induced by BDL for 2 weeks in *Reelin^{CreERT2}; R26T/G^f* mice. **B.** α -SMA and Col1a1 expression was significantly increased in BDL-operated
582 *Reelin^{CreERT2}; R26T/G^f* mice. **C.** Immunohistochemistry for CK19, GS and Sirius red indicated that BDL
583 caused biliary duct hyperplasia and biliary fibrosis, whereas CCl₄ led to pericentral cell injury and fibrosis
584 and forming fibrous septum. Data are reported as means \pm SEM. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. Scale
585 bar in A represents 100 μ m. Scale bar in B represents 20 μ m. Scale bar in C immunohistochemistry
586 pictures represents 50 μ m and in Sirius red staining represents 100 μ m.
587



588

589 **Supplemental Figure 2. CCl₄ induces severe pericentral fibrosis.**

590 **A.** Severe pericentral fibrosis was induced by CCl₄ for 6 weeks in Reelin^{CreERT2}; R26T/G^f mice observed
591 by sirius red staining. **B.** α-SMA and Col1a1 expression were significantly increased in CCl₄-treated
592 Reelin^{CreERT2}; R26T/G^f mice for 6 weeks. **C.** Sirius red staining indicated that after 5 weeks recovery from
593 CCl₄, fibrotic livers recovered to normal state. Data are reported as means ± SEM. *p < 0.05; **p < 0.01;
594 ***p < 0.001. Scale bar in A and C represents 100 μm. Scale bar in B represents 20 μm.



595

596 **Supplemental Figure 3. The characteristics of Vimentin⁺ HSCs are consistent with Desmin⁺ HSCs**
 597 **in BDL-induced and CCl₄-induced liver fibrosis.**

598 **A.** Serial sections immunostaining of Vimentin and Desmin indicated that the number and distribution of
 599 Vimentin⁺ HSCs were consistent with Desmin⁺ HSCs in sham-operated and BDL-operated Reelin^{CreERT2};
 600 R26T/G^f mouse livers. **B.** Serial sections immunostaining of mGFP and Desmin or Vimentin determined
 601 that the percentage of mGFP⁺ HSCs accounted for Desmin⁺ HSCs was similar to accounted for Vimentin⁺
 602 HSCs in sham-operated and BDL-operated Reelin^{CreERT2}; R26T/G^f mouse livers. **C.** Serial sections
 603 immunostaining of Vimentin and Desmin indicated that the number and distribution of Vimentin⁺ HSCs
 604 were consistent with Desmin⁺ HSCs in normal and CCl₄-treated Reelin^{CreERT2}; R26T/G^f mouse livers. **D.**
 605 Serial sections immunostaining of mGFP and Desmin or Vimentin indicated that the percentage of mGFP⁺
 606 HSCs accounted for Desmin⁺ HSCs was similar to accounted for Vimentin⁺ HSCs in in normal and CCl₄-
 607 treated Reelin^{CreERT2}; R26T/G^f mouse livers. Data are reported as means ± SEM. *p < 0.05; **p < 0.01; ***p
 608 < 0.001. Scale bar represents 20 μm.

609 **References**

- 610 1. Faini G, Del Bene F, Albadri S. Reelin functions beyond neuronal migration: from synaptogenesis
611 to network activity modulation. *Curr Opin Neurobiol.* 2021;66:135-43.
- 612 2. Khialeeva E, Chou JW, Allen DE, Chiu AM, Bensinger SJ, Carpenter EM. Reelin Deficiency Delays
613 Mammary Tumor Growth and Metastatic Progression. *J Mammary Gland Biol Neoplasia.* 2017;22(1):59-
614 69.
- 615 3. Ishii K, Kubo KI, Nakajima K. Reelin and Neuropsychiatric Disorders. *Front Cell Neurosci.*
616 2016;10:229.
- 617 4. Smalheiser NR, Costa E, Guidotti A, Impagnatiello F, Auta J, Lacor P, Kriho V, Pappas GD. Expression
618 of reelin in adult mammalian blood, liver, pituitary pars intermedia, and adrenal chromaffin cells.
619 *Proceedings of the National Academy of Sciences.* 2000;97(3):1281-6.
- 620 5. Botella-Lopez A, de Madaria E, Jover R, Bataller R, Sancho-Bru P, Candela A, Compan A, Perez-
621 Mateo M, Martinez S, Saez-Valero J. Reelin is overexpressed in the liver and plasma of bile duct ligated
622 rats and its levels and glycosylation are altered in plasma of humans with cirrhosis. *Int J Biochem Cell*
623 *Biol.* 2008;40(4):766-75.
- 624 6. Kobold D, Grundmann A, Piscaglia F, Eisenbach C, Neubauer K, Steffgen J, Ramadori G, Knittel T.
625 Expression of reelin in hepatic stellate cells and during hepatic tissue repair: a novel marker for the
626 differentiation of HSC from other liver myofibroblasts. *J Hepatol.* 2002;36(5):607-13.
- 627 7. Carotti S, Perrone G, Amato M, Vespasiani Gentilucci U, Righi D, Francesconi M, Pellegrini C, Zalfa
628 F, Zingariello M, Picardi A, Onetti Muda A, Morini S. Reelin expression in human liver of patients with
629 chronic hepatitis C infection. *Eur J Histochem.* 2017;61(1):2745.
- 630 8. Lua I, Li Y, Zagory JA, Wang KS, French SW, Sevigny J, Asahina K. Characterization of hepatic stellate
631 cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers. *J Hepatol.* 2016;64(5):1137-
632 46.
- 633 9. Lotto J, Drissler S, Cullum R, Wei W, Setty M, Bell EM, Boutet SC, Nowotschin S, Kuo YY, Garg V,
634 Pe'er D, Church DM, Hadjantonakis AK, Hoodless PA. Single-Cell Transcriptomics Reveals Early
635 Emergence of Liver Parenchymal and Non-parenchymal Cell Lineages. *Cell.* 2020;183(3):702-16 e14.
- 636 10. Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. *Adv Drug*
637 *Deliv Rev.* 2017;121:27-42.
- 638 11. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. *Nature Reviews*
639 *Gastroenterology & Hepatology.* 2017;14(7):397-411.
- 640 12. Yin C, Evason KJ, Asahina K, Stainier DY. Hepatic stellate cells in liver development, regeneration,
641 and cancer. *J Clin Invest.* 2013;123(5):1902-10.
- 642 13. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. *Annu Rev Pathol.* 2011;6:425-56.
- 643 14. Lemoinne S, Cadoret A, El Mourabit H, Thabut D, Housset C. Origins and functions of liver
644 myofibroblasts. *Biochim Biophys Acta.* 2013;1832(7):948-54.
- 645 15. Li J, Tuo B. Current and Emerging Approaches for Hepatic Fibrosis Treatment. *Gastroenterology*
646 *research and practice.* 2021;2021:6612892.
- 647 16. Herrera J, Henke CA, Bitterman PB. Extracellular matrix as a driver of progressive fibrosis. *J Clin*
648 *Invest.* 2018;128(1):45-53.
- 649 17. Kisseleva T. The origin of fibrogenic myofibroblasts in fibrotic liver. *Hepatology.* 2017;65(3):1039-
650 43.

- 651 18. Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, Liu X, Xu J, Wang P, Paik YH, Meng
652 F, Asagiri M, Murray LA, Hofmann AF, Iida T, Glass CK, Brenner DA, Kisseleva T. Origin of myofibroblasts
653 in the fibrotic liver in mice. *Proc Natl Acad Sci U S A*. 2014;111(32):E3297-305.
- 654 19. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, Pradere JP, Schwabe RF. Fate
655 tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its
656 aetiology. *Nature communications*. 2013;4:2823.
- 657 20. Pei D, Shu X, Gassama-Diagne A, Thiery JP. Mesenchymal-epithelial transition in development and
658 reprogramming. *Nat Cell Biol*. 2019;21(1):44-53.
- 659 21. Xie G, Diehl AM. Evidence for and against epithelial-to-mesenchymal transition in the liver. *Am J*
660 *Physiol Gastrointest Liver Physiol*. 2013;305(12):G881-90.
- 661 22. Choi SS, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. *Hepatology*.
662 2009;50(6):2007-13.
- 663 23. Yang L, Jung Y, Omenetti A, Witek RP, Choi S, Vandongen HM, Huang J, Alpini GD, Diehl AM. Fate-
664 mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. *Stem Cells*.
665 2008;26(8):2104-13.
- 666 24. Swiderska-Syn M, Syn WK, Xie G, Kruger L, Machado MV, Karaca G, Michelotti GA, Choi SS,
667 Premont RT, Diehl AM. Myofibroblastic cells function as progenitors to regenerate murine livers after
668 partial hepatectomy. *Gut*. 2014;63(8):1333-44.
- 669 25. Michelotti GA, Xie G, Swiderska M, Choi SS, Karaca G, Kruger L, Premont R, Yang L, Syn WK,
670 Metzger D, Diehl AM. Smoothed is a master regulator of adult liver repair. *J Clin Invest*.
671 2013;123(6):2380-94.
- 672 26. Scholten D, Österreicher CH, Scholten A, Iwaisako K, Gu G, Brenner DA, Kisseleva T. Genetic
673 Labeling Does Not Detect Epithelial-to-Mesenchymal Transition of Cholangiocytes in Liver Fibrosis in
674 Mice. *Gastroenterology*. 2010;139(3):987-98.
- 675 27. Lua I, James D, Wang J, Wang KS, Asahina K. Mesodermal mesenchymal cells give rise to
676 myofibroblasts, but not epithelial cells, in mouse liver injury. *Hepatology*. 2014;60(1):311-22.
- 677 28. Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, Pradere JP, Friedman RA, Schwabe
678 RF. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. *Gastroenterology*.
679 2012;143(4):1073-83 e22.
- 680 29. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B,
681 Tsukamoto H, Evans SM, Dillmann W, Glass CK, Brenner DA. Myofibroblasts revert to an inactive
682 phenotype during regression of liver fibrosis. *Proc Natl Acad Sci U S A*. 2012;109(24):9448-53.
- 683 30. Rosenthal SB, Liu X, Ganguly S, Dhar D, Pasillas MP, Ricciardelli E, Li RZ, Troutman TD, Kisseleva T,
684 Glass CK, Brenner DA. Heterogeneity of HSCs in a Mouse Model of NASH. *Hepatology*. 2021;74(2):667-
685 85.
- 686 31. Tao LL, Cheng YY, Ding D, Mei S, Xu JW, Yu J, Ou-Yang Q, Deng L, Chen Q, Li QQ, Xu ZD, Liu XP.
687 C/EBP-alpha ameliorates CCl(4)-induced liver fibrosis in mice through promoting apoptosis of hepatic
688 stellate cells with little apoptotic effect on hepatocytes in vitro and in vivo. *Apoptosis : an international*
689 *journal on programmed cell death*. 2012;17(5):492-502.
- 690 32. Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, Thoen LFR, Hoorens A, Reynaert H,
691 Halder G, van Grunsven LA. The Hippo pathway effector YAP controls mouse hepatic stellate cell
692 activation. *J Hepatol*. 2015;63(3):679-88.

- 693 33. Hyun J, Wang S, Kim J, Rao KM, Park SY, Chung I, Ha CS, Kim SW, Yun YH, Jung Y. MicroRNA-378
694 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression. *Nature*
695 *communications*. 2016;7:10993.
- 696 34. Zheng L, Zhao Z, Lin J, Li H, Wu G, Qi X, Lou X, Bao Y, Huo H, Luo M. Telmisartan relieves liver
697 fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction. *Eur J*
698 *Pharmacol*. 2022;915:174713.
- 699 35. Forbes SJ, Parola M. Liver fibrogenic cells. *Best Pract Res Clin Gastroenterol*. 2011;25(2):207-17.
- 700 36. Yanguas SC, Cogliati B, Willebrords J, Maes M, Colle I, van den Bossche B, de Oliveira C, Andraus
701 W, Alves VAF, Leclercq I, Vinken M. Experimental models of liver fibrosis. *Arch Toxicol*. 2016;90(5):1025-
702 48.
- 703 37. Moghadamrad S, Hassan M, McCoy KD, Kirundi J, Kellmann P, De Gottardi A. Attenuated fibrosis
704 in specific pathogen-free microbiota in experimental cholestasis- and toxin-induced liver injury. *FASEB*
705 *J*. 2019;33(11):12464-76.
- 706 38. Wu L, Zhang Q, Mo W, Feng J, Li S, Li J, Liu T, Xu S, Wang W, Lu X, Yu Q, Chen K, Xia Y, Lu J, Xu L,
707 Zhou Y, Fan X, Guo C. Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation
708 and reducing autophagy via the TGF- β 1/Smads and PI3K/Akt pathways. *Sci Rep*. 2017;7(1):9289.
- 709 39. Krenkel O, Hundertmark J, Ritz TP, Weiskirchen R, Tacke F. Single Cell RNA Sequencing Identifies
710 Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis. *Cells*. 2019;8(5):503.
- 711 40. Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, Portman JR,
712 Matchett KP, Brice M, Marwick JA, Taylor RS, Efremova M, Vento-Tormo R, Carragher NO, Kendall TJ,
713 Fallowfield JA, Harrison EM, Mole DJ, Wigmore SJ, Newsome PN, Weston CJ, Iredale JP, Tacke F, Pollard
714 JW, Ponting CP, Marioni JC, Teichmann SA, Henderson NC. Resolving the fibrotic niche of human liver
715 cirrhosis at single-cell level. *Nature*. 2019;575(7783):512-8.
- 716 41. Chen Z, Wan L, Jin X, Wang W, Li D. Transforming growth factor- β signaling confers hepatic stellate
717 cells progenitor features after partial hepatectomy. *J Cell Physiol*. 2020;235(3):2655-67.
- 718 42. Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A, Costa E. Reelin promoter
719 hypermethylation in schizophrenia. *Proc Natl Acad Sci U S A*. 2005;102(26):9341-6.
- 720 43. Mansy SS, Nosseir MM, Zoheiry MA, Hassanein MH, Guda MF, Othman MM, AbuTalab H. Value of
721 reelin for assessing hepatic fibrogenesis in a group of Egyptian HCV infected patients. *Clin Chem Lab*
722 *Med*. 2014;52(9):1319-28.
- 723 44. Koyama Y, Brenner DA. Liver inflammation and fibrosis. *J Clin Invest*. 2017;127(1):55-64.
- 724 45. Stradiot L, Verhulst S, Roosens T, Oie CI, Moya IM, Halder G, Mannaerts I, van Grunsvan LA.
725 Functionality based method for simultaneous isolation of rodent hepatic sinusoidal cells. *Biomaterials*.
726 2017;139:91-101.
- 727 46. Fuji H, Miller G, Nishio T, Koyama Y, Lam K, Zhang V, Loomba R, Brenner D, Kisseleva T. The role of
728 Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis. *Frontiers in*
729 *molecular biosciences*. 2021;8:790032.
- 730 47. Nishio T, Hu R, Koyama Y, Liang S, Rosenthal SB, Yamamoto G, Karin D, Baglieri J, Ma HY, Xu J, Liu
731 X, Dhar D, Iwaisako K, Taura K, Brenner DA, Kisseleva T. Activated hepatic stellate cells and portal
732 fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. *J Hepatol*. 2019;71(3):573-
733 85.
- 734 48. Georgiev P, Jochum W, Heinrich S, Jang JH, Nocito A, Dahm F, Clavien PA. Characterization of time-
735 related changes after experimental bile duct ligation. *Br J Surg*. 2008;95(5):646-56.

736